Deconstruyendo los fenotipos en la EPOC: un análisis de la cohorte TRACE

Hernández, Laura Carrasco; Eraso, Candela Caballero; Ruiz-Duque, Borja; Arranz, María Abad; Martín, Eduardo Márquez; Acuña, Carmen Calero; Lόpez-Campos, José Luís

doi:10.1016/j.arbres.2020.12.010

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 Others have proposed a phenotype-based approach which has also gained popularity via the Spanish Guidelines for COPD (GesEPOC). 6 Although both initiatives have benefits and drawbacks, 7,8 they provide an opportunity for clinicians to manage COPD more successfully in their daily clinical practice. Nowadays, at the start of this new decade, COPD management has progressed to the stage where specific patient-based recommendations can be provided.…”

Section: Introductionmentioning

confidence: 99%

Step-Up and Step-Down Treatment Approaches for COPD: A Holistic View of Progressive Therapies

Lόpez-Campos¹,

Hernández²,

Ruiz-Duque³

et al. 2021

COPD

Self Cite

View full text Add to dashboard Cite

Recent advances in inhaled drugs and a clearer definition of the disease have made the task of managing COPD more complex. Different proposals have been put forward which combine all the available treatments and the different clinical presentations in an effort to select the best therapeutic options for each clinical context. As COPD is a chronic progressive disease, the escalation of therapy has traditionally been considered the most natural way to tackle it. However, the notion of COPD as a constantly progressing disease has recently been challenged and, in specific areas, this points to the possibility of a deescalation in treatment. In this context, the clinician requires simple, specific recommendations to guide these changes in treatment in their daily clinical practice. To accomplish this, the first step must be a correct evaluation and an accurate initial preliminary diagnosis of the patient's condition. Thereafter, the first escalation in therapy must be introduced with caution as the disease progresses, since clinical trials are not designed with clinical decision-making in mind. During this escalation, three possibilities are open to change the current treatment for a different one within the same family, to increase non-pharmacological interventions or to increase the pharmacological therapies. Beyond that point, a patient with persistent symptoms represents a complex clinical scenario which requires a specialized approach, including the evaluation of different respiratory and non-respiratory comorbidities. Unfortunately, there are few de-escalation studies available, and these are mainly observational in nature. The debate on de-escalation in pharmacological treatment, therefore, involves two main discussion points: the withdrawal of bronchodilators and the withdrawal of inhaled steroids. Altogether, the scheme for modifying treatment must be more personalized than just adding molecules, and the therapeutic response and its conditioning factors should be evaluated at each step before proceeding further.

show abstract